retatrutide clinical trial results safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Results: 24% Weight Loss
Pay in 4 interest-free payments of $7.24 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9














/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)













